Medical marijuana had a yuge win on election day.
In each state where the issue was on the ballot—Florida, Arkansas, Montana, and North Dakota—voters supported initiatives that would provide or expand patients’ access to cannabis products for ailments that include post-traumatic stress disorder, epilepsy, Parkinson’s disease, cancer, and glaucoma.
All told, 29 states and the District of Columbia now have legislation permitting medical marijuana.
But come January, will the Trump administration allow this to continue?
That’s a question, because while the states may be the laboratories of democracy, the United States government is the ultimate arbiter in this case. Under federal law, marijuana, regardless of its intended use, remains illegal.
The Drug Enforcement Administration (DEA) has signaled that it prefers to keep it that way. In August, the government agency announced that it would continue to classify marijuana as a Schedule I substance—placing it in the same category as heroin, LSD, and other drugs that have a high potential for abuse and no medical value.